About mind medicine (mindmed) - MNMD
Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.
MNMD At a Glance
Mind Medicine (MindMed), Inc.
One World Trade Center
New York, New York 10007
| Phone | 1-212-220-6633 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -108,679,000.00 | |
| Sector | Health Technology | Employees | 74 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
MNMD Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.165 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.307 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.092 |
MNMD Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,468,635.135 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
MNMD Liquidity
| Current Ratio | 7.249 |
| Quick Ratio | 7.249 |
| Cash Ratio | 7.046 |
MNMD Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -50.94 |
| Return on Equity | -68.013 |
| Return on Total Capital | -41.275 |
| Return on Invested Capital | -61.13 |
MNMD Capital Structure
| Total Debt to Total Equity | 9.051 |
| Total Debt to Total Capital | 8.30 |
| Total Debt to Total Assets | 7.233 |
| Long-Term Debt to Equity | 9.051 |
| Long-Term Debt to Total Capital | 8.30 |